According to Fitch, after acquiring EHR vendor Cerner in June, Oracle has constrained additional debt issuances and share buybacks and is focusing instead on repaying maturities through fiscal 2024.
With the projected EBITDA leverage staying below 3.5 times, Fitch said it anticipates that in fiscal 2025, the company will resume activities such as debt refinancing and share buybacks, all while ensuring that EBITDA leverage remains below 3.5 times.
Following a temporary dip in EBITDA margins following the acquisition of Cerner, Oracle has seen a rebound in profitability the past few quarters, nearing levels seen before the acquisition, according to Fitch.
Fitch anticipates a trajectory toward 50% EBITDA margins in the intermediate term as Cerner becomes fully integrated, and Oracle’s sustained growth in cloud products is expected to mitigate a decline in on-premise products.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
